[Alpha Biz=(Chicago) Reporter Paul Lee] Invitros, a company specializing in in vitro diagnosis, has signed a contract with Roche, a global big pharma company, to supply more than 160 billion won over the next 10 years.
The contract was made last year after LG Chem moved its nest to PEF (Private Equity) Glenwood PE (Glanwood Private Equity).
According to related industries on the 23rd, Invitros recently signed an exclusive manufacturing and supply contract with Roche, a global pharmaceutical company, for vacuum blood vessels for latent tuberculosis in vitro diagnosis.
Invitros' latent tuberculosis products are already used by various organizations with the approval of the Ministry of Food and Drug Safety. It is expected that know-how on Invitros' latent tuberculosis diagnosis products secured in Korea will help Roche advance into the global market.
The origin of Invitros is LG Chem. Glenwood PE changed its name to Invitros after acquiring LG Chem's In Vitro Diagnostics Division in October last year. Starting with diagnostic reagent research in 1986, reagents and equipment necessary for in vitro diagnosis such as molecular diagnosis and immune diagnosis are developed, manufactured, and sold. In particular, it has maintained its market share for more than 10 years since its launch based on its relatively high expertise in tuberculosis and allergy diagnosis.
After Glanwood PE acquired it, it became independent as a new corporation called Invitros and has since actively invested in human resources, facilities, and R & D (research and development).
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
